B. Braun Launches New Dialyzer

BETHLEHEM, Pa., Aug. 21, 2017 -- B. Braun Medical Inc. today announced that the U.S. Food and Drug Administration has cleared its hemodialyzer, Diacap^® Pro. This new dialyzer has improved clearance performance and user handling.

Diacap Pro Group

A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/03799a24-0338-4711-a708-24c4ed7de1a9

A dialyzer, also known as an “artificial kidney,” is a hemodialysis filter that removes wastes and excess fluid from the blood when a patient’s kidneys can no longer perform the task. Diacap Pro’s advances in fiber technology provide a lower comparable surface area and an increased molecule to surface contact.

“The newly developed fibers in Diacap Pro are designed to improve dialysis dose,” said Samuel Amory, Vice President at B. Braun Medical. “The Diacap Pro fibers clear blood toxins like urea and creatinine, while still retaining vital molecules like albumin. It is our newest hemodialysis product innovation, and fits well with our other products including the Dialog^+® Hemodialysis System, Solcart^® bicarbonate cartridge, and the AQUAboss^® Water Treatment System.”

Diacap Pro is available in three distinct sizes (1.3m², 1.6m², 1.9m²), which address the different patient needs.

B. Braun has provided innovative products to the dialysis community for more than 35 years. Its Dialog+ Hemodialysis System incorporates leading-edge technology in dialysis, and its dialysis product line offers an array of disposable products that allow healthcare professionals to tailor treatments for their patients.

To learn more, call the B. Braun Renal Therapies customer service line at 800-848-2066 or visit www.BBraunUSA.com/Diacap.

About B. Braun
B. Braun Medical Inc. markets innovative medical products and services to the healthcare industry. As a manufacturer and distributor of hemodialysis equipment and related disposables, including the Diacap @ Polysulfone^® dialyzers and Medisystems’ Streamline Bloodlines, the Renal Therapies Division of B. Braun is committed to the continued development of high quality products for hemodialysis and continuous renal replacement therapy supported by a team of clinical nurses, field service personnel, customer service and 24/7 technical assistance.

B. Braun Medical is headquartered in Bethlehem, Pa., and is part of the B. Braun Group of Companies in the U.S., which includes B. Braun Interventional Systems, Aesculap^® and CAPS^®.

Globally, the B. Braun Group of Companies employs more than 58,000 employees in 64 countries. Guided by its Sharing Expertise^® philosophy, B. Braun continuously exchanges knowledge with customers, partners and clinicians to address the critical issues of improving care and lowering costs.

To learn more about B. Braun Medical, visit www.BBraunUSA.com. 

Contact:
Jason Ford
B. Braun Medical Inc.
610.997.4722
[email protected]